Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.
The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery. The three medications are pembrolizumab, olaparib, and temozolomide. 
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
Researchers want to find the best dose of TNG456 to use alone or with abemaciclib to treat brain cancer. The people in this study have glioblastoma that has spread. In addition, their cancer is missing a protein called MTAP.
Researchers want to see how well cabozantinib works to treat meningioma, a type of brain tumor. The people in this study have meningiomas that came back or keep growing even after treatment.
Glioblastomas that have an "unmethylated" MGMT gene are less likely to respond to the standard chemotherapy drug temozolomide. In this study, researchers are comparing three investigational treatments (abemaciclib, CC-115, and neratinib) with the standard treatment (temozolomide and radiation therapy) in patients newly diagnosed with glioblastoma.
